FASN and metabolic dysfunction-associated steatohepatitis: In the context of MSC-mediated upregulation of FASN and monoacylglycerol acyltransferase 1 (MOGAT1) in the NASH livers (Figure 3C), it may be suggested that MSC treatment fuels fatty acids into triglyceride and VLDL synthesis and secretion, thus accounting for the attenuating of lipid content in the NASH livers with MSC treatment (cf. Figure 2).